Partnerships

Business Outreach

We have established numerous strategic collaborations to increase our pipeline of assets, explore new treatment areas, and advance our oncology programs to broaden the patient populations we serve.

Our Partners

Chia Tai Tiangqing

We have the rights to APL-502 outside mainland China. Chia Tai TianQing Pharmaceutical Group (CTTQ Pharma) has development and commercialization rights in mainland China for APL-502 where it is referred to as TQB2450.

Genor Biopharma

We have the rights to APL-501 outside mainland China. Genor BioPharma Co., Ltd., now part of Edding Genor Group, has development and commercialization rights in mainland China for APL-501, where it is referred to as GB226.

Beijing Avistone

Beijing Pearl Biotechnology Co., Ltd., a wholly owned subsidiary of Beijing Avistone Biotechnology Co., Ltd.

We have the rights to APL-101 outside mainland China, Hong Kong and Macau. Beijing Pearl Biotechnology Co., Ltd. has the exclusive rights in mainland China, Hong Kong and Macau for APL-101 where it is referred to as PLB1001.